EMEA-002292-PIP01-17

Key facts

Active substance
Rovalpituzumab tesirine
Therapeutic area
Oncology
Decision number
P/0116/2018
PIP number
EMEA-002292-PIP01-17
Pharmaceutical form(s)
Powder and solvent for concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of lung carcinoma (small cell and non-small cell carcinoma)
Route(s) of administration
Intravenous use
Contact for public enquiries
AbbVie Ltd

Tel.: +44 1628561090
E-mail: paediatricteam@abbvie.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating